Showing Results for
- Academic Journals (11)
Search Results
- 11
Academic Journals
- 11
-
From:Journal of Experimental & Clinical Cancer Research (Vol. 41, Issue 1) Peer-ReviewedBackground We recently conducted Cetuximab-AVElumab-Lung (CAVE-Lung), a proof-of-concept, translational and clinical trial, to evaluate the combination of two IgG1 monoclonal antibodies (mAb): avelumab, an anti-PD-L1...
-
From:Journal of Experimental & Clinical Cancer Research (Vol. 38, Issue 1) Peer-ReviewedBackground Anti-PD-1/PD-L1 drugs are effective as monotherapy in a proportion of NSCLC patients and there is a strong rationale for combining them with targeted therapy. Inhibition of MAPK pathway may have...
-
From:Journal of Experimental & Clinical Cancer Research (Vol. 38, Issue 1) Peer-ReviewedBackground Previous studies showed that the combination of an anti-Epidermal growth factor (EGFR) and a MEK-inhibitor is able to prevent the onset of resistance to anti-EGFR monoclonal antibodies in KRAS-wild type...
-
From:Journal of Experimental & Clinical Cancer Research (Vol. 38, Issue 1) Peer-ReviewedBackground Targeting the epidermal growth factor receptor (EGFR) either alone or in combination with chemotherapy is an effective treatment for patients with RAS wild-type metastatic colorectal cancer (mCRC)....
-
From:Journal of Experimental & Clinical Cancer Research (Vol. 40, Issue 1) Peer-ReviewedBackground Despite the advancements in new therapies for colorectal cancer (CRC), chemotherapy still constitutes the mainstay of the medical treatment. For this reason, new strategies to increase the efficacy of...
-
From:Journal of Experimental & Clinical Cancer Research (Vol. 38, Issue 1) Peer-ReviewedBackground Pioglitazone, a synthetic peroxisome proliferator activated receptor (PPAR-[gamma]) ligand, is known as an antidiabetic drug included in the thiazolidinediones (TZDs) class. It regulates the lipid and...
-
From:PLoS ONE (Vol. 6, Issue 12) Peer-ReviewedTreatment of non small cell lung cancer (NSCLC) and colorectal cancer (CRC) have substantially changed in the last years with the introduction of epidermal growth factor receptor (EGFR) inhibitors in the clinical...